Forbes contributors publish independent expert analyses and insights. I write about green businesses and how to help startups succeed. This article is more than 10 years old. Think of the last time ...
BRISBANE, Calif., June 21, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced the upcoming presentation of data from the Phase 1/2 Alta study ...
HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a late-breaking presentation ...
Two poster presentations at AAIC provide early evidence of the value of ultra-low-field Swoop® system MR brain images in ARIA-E detection and morphography evaluation in patients with Alzheimer's ...
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) today announced that the Company will present new data from across its oncology portfolio at the 2024 American Society of Hematology (ASH) ...
- All key study objectives regarding pharmacokinetic, pharmacodynamic, safety, and clinical activity were met - - Complete remission (CR) achieved after three months of treatment with duration of ...
Company’s AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other ...
NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback